PARP1 and thyroid gland carcinoma: Therefore, our results imply that SLC6A9 acts as a stabilizer for 131I sensitivity by maintaining PARP-1 expression and may serve as a novel therapeutic agent for thyroid cancer patients with 131I treatment failure.